JPS6353984B2 - - Google Patents

Info

Publication number
JPS6353984B2
JPS6353984B2 JP16290980A JP16290980A JPS6353984B2 JP S6353984 B2 JPS6353984 B2 JP S6353984B2 JP 16290980 A JP16290980 A JP 16290980A JP 16290980 A JP16290980 A JP 16290980A JP S6353984 B2 JPS6353984 B2 JP S6353984B2
Authority
JP
Japan
Prior art keywords
acid
group
general formula
reaction
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP16290980A
Other languages
Japanese (ja)
Other versions
JPS5785346A (en
Inventor
Kanji Noda
Akira Nakagawa
Toshiharu Motomura
Masayoshi Tsuji
Juji Shimozono
Hiroyuki Ide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Priority to JP16290980A priority Critical patent/JPS5785346A/en
Publication of JPS5785346A publication Critical patent/JPS5785346A/en
Publication of JPS6353984B2 publication Critical patent/JPS6353984B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は一般式() 〔式中、Aは The present invention is based on the general formula () [In the formula, A is

【式】(但し、式中Yは水 素原子、ハロゲン原子、低級アルコキシ基、ニト
ロ基、アミノ基又はトリフルオロメチル基を意味
する)又はピリジル基を意味する〕で表わされる
新規なシクロヘキサンカルボン酸誘導体に関する
ものである。 前記一般式()におけるAについて更に具体
的に説明すると、Aの
A novel cyclohexanecarboxylic acid derivative represented by the formula It is related to. To explain A in the general formula () more specifically, A's

【式】におけるY なる置換基は水素原子、ハロゲン原子(例えば塩
素、臭素、沃素、弗素等)、低級アルコキシ基
(例えばメトキシ基、エトキシ基、プロポキシ基、
ブトキシ基等)、ニトロ基、アミノ基等が任意の
位置に1〜3個置換されることを意味し、又、ピ
リジル基は2−ピリジル基、3−ピリジル基、4
−ピリジル基を意味する。 近年、抗プラスミン作用を有するトランス−4
−アミノメチルシクロヘキサンカルボン酸(トラ
ネキサム酸)及びその誘導体に関する研究が活発
に行なわれ、抗潰瘍作用、抗腫瘍作用等の薬理作
用が見出された。又、トラネキサム酸は作用は弱
いが抗補体作用を有することが報告されている。 そこで本発明者等はトラネキサム酸の抗補体作
用に興味を持ち、更に優れた作用を有する薬剤の
開発を目的として、一連の新規なトラネキサム酸
誘導体の合成を行ないその薬理作用の検索を行な
つた。その結果、本発明の化合物は顕著な抗補体
作用を有し、腎炎、リウマチ、膠原病、自己免疫
疾患等のアレルギー性疾患の予防及び治療剤とし
て有用であることが判明した。又抗プラスミン、
抗腫瘍、抗潰瘍、抗血栓、抗コレステロール作用
をも有し、医薬品として有用な化合物である。 本発明に係る一般式()で示されるシクロヘ
キサンカルボン酸誘導体は以下に示す製造法に従
つて製造される。 但し、式中Aは前記と同じ意味を有する。 但し、式中Aは前記と同じ意味を有する。 但し、式中Xは塩素原子及び臭素原子等のハロ
ゲン原子又は反応性スルホン酸残基を意味し、A
は前記と同じ意味を有する。 前記各製造法について更に具体的に説明する
と、製造法Aは一般式()で表わされるトラネ
キサム酸と一般式()で表わされる芳香族アル
デヒドを反応に関与しない有機溶媒(例えばメタ
ノール、エタノール、テトラヒドロフラン、ジグ
リム等)中、還元剤(例えばパラジウム−カーボ
ン等)を加えて室温もしくは加熱下において常圧
又は加圧下(0.1〜10Kg/cm)で反応を行うこと
により一般式()で表わされる目的化合物を得
ることができる。 製造法Bは一般式()で表わされるシツフ塩
基誘導体を還元剤(例えば水素化ホウ素ナトリウ
ム、水素化ホウ素カリウム、パラジウム−カーボ
ン等)の存在下、反応に関与しない有機溶媒(例
えば水、メタノール、エタノール、テトラヒドロ
フラン、酢酸等)中、氷冷下あるいは室温又は加
熱下において、常圧又は加圧下(0.1〜10Kg/cm2
で反応を行うことにより一般式()で表わされ
る目的化合物を得ることができる。 製造法Cは一般式()で表わされる反応性誘
導体を反応に関与しない有機溶媒(水、テトラヒ
ドロフラン、ジオキサン、ベンゼン、トルエン、
キシレン、ピリジン、ジメチルホルムアミド、ヘ
キサメチルホスホリツクトリアミド等)中、加熱
下において反応を行なうことにより一般式()
で表わされる目的化合物を得ることができる。 製造法Dは一般式()で表わされるニトロ体
を還元剤(ラネ−ニツケル、酸化白金、パラジウ
ム−カーボン等)の存在下、反応に関与しない有
機溶媒(例えばメタノール、エタノール、酢酸
等)中、室温又は加熱下に常圧あるいは加圧下で
反応を行なうことにより一般式()で表わされ
るアミノ体を好収率で得ることができる。 かくして得られた化合物は所望により無機塩
(例えばカリウム、カルシウム、ナトリウム、ア
ルミニウム、塩酸等)又は有機塩(例えばアルギ
ニン、リジン等のアミノ酸塩及びジメチルアミノ
エタノール等)に導くことができる。 以下に実施例を示し本発明を更に具体的に説明
する。 実施例 1 メタノール50ml中にトランス−4−ベンジリデ
ンアミノメチルシクロヘキサンカルボン酸2.45g
を加え、氷冷下に水素化ホウ素ナトリウム0.76g
を徐々に加えた。次いで室温の状態で8時間反応
させ、溶媒を減圧下にて留去し残渣に水を加え希
酢酸にて弱酸性とし、析出する結晶を取、乾燥
後、エタノール−水(8:2)にて再結晶すると
無色プリズム晶のトランス−4−ベンジルアミノ
メチルシクロヘキサンカルボン酸2.2gを得た。 この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。 融点 233〜235℃ 赤外吸収スペクトル νc=o 1640cm-1 マススペクトル M+ 247 元素分析値 C15H21NO2 理論値 C:72.84 H:8.56 N:5.66 実測値 C:72.96 H:8.43 N:5.82 実施例 2 エタノール150ml中にトランス−4−(p−クロ
ルベンジリデン)アミノメチルシクロヘキサンカ
ルボン酸2.8g及び10%のパラジウム−カーボン
1.0gを加え接触還元を0.5Kg/cm2にて行なつた。
理論量の水素を吸収した時点で反応をやめ、反応
溶液を過し、液を減圧下に濃縮すると結晶が
析出するのでこれを取、乾燥後更にアセトンに
て再結晶すると無色プリズム晶のトランス−4−
(p−クロルベンジル)アミノメチルシクロヘキ
サンカルボン酸2.6gを得た。 この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。 融点 225〜226℃ 赤外吸収スペクトル νc=o 1640cm-1 マススペクトル M+ 281 元素分析値 C15H20ClNO2 理論値 C:63.71 H:7.13 N:4.95 実測値 C:63.82 H:7.05 N:4.88 実施例 3 トランス−4−アミノメチルシクロヘキサンカ
ルボン酸3.14gと−イソニコチンアルデヒド2.14
g及び10%パラジウム−カーボン2.5gをエタノ
ール100ml中に加え80〜100℃に加熱下接触還元を
4時間行なつた。反応溶液を過し液を減圧濃
縮し、析出する結晶を取、更にメタノールより
再結晶すると無色プリズム晶のトランス−4−
(4′−ピリジルメチル)アミノメチルシクロヘキ
サンカルボン酸2.5gを得た。 この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。 融点 186〜188℃ 赤外吸収スペクトル νc=o マススペクトル M+ 248 元素分析値 C14H20N2O2 理論値 C:67.71 H:8.12 N:11.28 実測値 C:67.61 H:8.04 N:11.36 実施例 4 トランス−4−(p−ニトロベンジル)アミノ
メチルシクロヘキサンカルボン酸2.9gと酸化白
金0.3gをメタノール酢酸(9.5:0.5)50ml中に加
え、室温下、1〜2Kg/cm2にて接触還元を行なつ
た。理論量の水素を吸収した時点で反応をやめ、
反応溶液を過し、液を減圧濃縮し、析出する
結晶を取、更にアセトン−イソプロピルエーテ
ルの混合溶媒より再結晶すると淡黄色プリズム晶
のトランス−4−(p−アミノベンジル)アミノ
メチルシクロヘキサンカルボン酸2.4gを得た。 この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。 融点 208〜210℃ 赤外吸収スペクトル νc=o マススペクトル M+ 262 元素分析値 C15H22N2O2 理論値 C:68.67 H:8.45 N:10.68 実測値 C:68.76 H:8.31 N:10.78 実施例 5〜12 実施例1〜4の方法に準じて次表の本発明化合
物を合成した。
The substituent Y in [Formula] is a hydrogen atom, a halogen atom (e.g., chlorine, bromine, iodine, fluorine, etc.), a lower alkoxy group (e.g., a methoxy group, an ethoxy group, a propoxy group,
butoxy group, etc.), nitro group, amino group, etc. at any position, and pyridyl group means 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, etc.
-Means a pyridyl group. In recent years, trans-4, which has an anti-plasmin effect, has been
-Aminomethylcyclohexanecarboxylic acid (tranexamic acid) and its derivatives have been actively researched, and pharmacological effects such as antiulcer and antitumor effects have been discovered. Furthermore, tranexamic acid has been reported to have anti-complementary action, although the action is weak. Therefore, the present inventors became interested in the anti-complementary action of tranexamic acid, and with the aim of developing a drug with even better action, we synthesized a series of new tranexamic acid derivatives and investigated their pharmacological actions. Ta. As a result, it was found that the compound of the present invention has a remarkable anti-complement effect and is useful as a prophylactic and therapeutic agent for allergic diseases such as nephritis, rheumatism, collagen disease, and autoimmune diseases. Also anti-plasmin,
It also has antitumor, antiulcer, antithrombotic, and anticholesterol effects, making it a useful compound as a pharmaceutical. The cyclohexanecarboxylic acid derivative represented by the general formula () according to the present invention is produced according to the production method shown below. However, A in the formula has the same meaning as above. However, A in the formula has the same meaning as above. However, in the formula, X means a halogen atom such as a chlorine atom and a bromine atom, or a reactive sulfonic acid residue, and A
has the same meaning as above. To explain each of the above-mentioned production methods in more detail, production method A uses tranexamic acid represented by the general formula () and an aromatic aldehyde represented by the general formula () in an organic solvent that does not participate in the reaction (for example, methanol, ethanol, tetrahydrofuran). , diglyme, etc.), add a reducing agent (e.g., palladium-carbon, etc.) and conduct the reaction at room temperature or under heating at normal pressure or under pressure (0.1 to 10 Kg/cm) to obtain the target compound represented by the general formula (). can be obtained. In production method B, a Schiff base derivative represented by the general formula () is treated in the presence of a reducing agent (e.g., sodium borohydride, potassium borohydride, palladium-carbon, etc.) in an organic solvent that does not participate in the reaction (e.g., water, methanol, ethanol, tetrahydrofuran, acetic acid, etc.) under ice-cooling, room temperature, or heating under normal pressure or increased pressure (0.1 to 10 Kg/cm 2 )
By carrying out the reaction, the target compound represented by the general formula () can be obtained. Production method C uses a reactive derivative represented by the general formula () in an organic solvent that does not participate in the reaction (water, tetrahydrofuran, dioxane, benzene, toluene,
By carrying out the reaction under heating in xylene, pyridine, dimethylformamide, hexamethylphosphoric triamide, etc.), the general formula ()
The target compound represented by can be obtained. Production method D involves the production of a nitro compound represented by the general formula () in the presence of a reducing agent (Raney-nickel, platinum oxide, palladium-carbon, etc.) in an organic solvent that does not participate in the reaction (for example, methanol, ethanol, acetic acid, etc.). The amino compound represented by the general formula () can be obtained in good yield by carrying out the reaction at room temperature or under heating and normal pressure or increased pressure. The compound thus obtained can be converted into an inorganic salt (eg, potassium, calcium, sodium, aluminum, hydrochloric acid, etc.) or an organic salt (eg, amino acid salts such as arginine, lysine, dimethylaminoethanol, etc.) as desired. EXAMPLES The present invention will be explained in more detail with reference to Examples below. Example 1 2.45 g of trans-4-benzylideneaminomethylcyclohexanecarboxylic acid in 50 ml of methanol
and 0.76g of sodium borohydride under ice cooling.
was added gradually. Next, the reaction was allowed to proceed at room temperature for 8 hours, the solvent was distilled off under reduced pressure, water was added to the residue, and the residue was made weakly acidic with dilute acetic acid. The precipitated crystals were collected, dried, and then dissolved in ethanol-water (8:2). Recrystallization was performed to obtain 2.2 g of colorless prismatic crystals of trans-4-benzylaminomethylcyclohexanecarboxylic acid. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 233-235℃ Infrared absorption spectrum νc=o 1640cm -1 Mass spectrum M + 247 Elemental analysis value C 15 H 21 NO 2 Theoretical value C: 72.84 H: 8.56 N: 5.66 Actual value C: 72.96 H: 8.43 N: 5.82 Example 2 2.8 g of trans-4-(p-chlorobenzylidene)aminomethylcyclohexanecarboxylic acid and 10% palladium-carbon in 150 ml of ethanol.
1.0 g was added to carry out catalytic reduction at 0.5 Kg/cm 2 .
When the theoretical amount of hydrogen has been absorbed, the reaction is stopped, the reaction solution is filtered, and the liquid is concentrated under reduced pressure to precipitate crystals, which are removed, dried, and then recrystallized with acetone to form colorless prism crystals. 4-
2.6 g of (p-chlorobenzyl)aminomethylcyclohexanecarboxylic acid was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 225-226℃ Infrared absorption spectrum νc=o 1640cm -1 Mass spectrum M + 281 Elemental analysis value C 15 H 20 ClNO 2 Theoretical value C: 63.71 H: 7.13 N: 4.95 Actual value C: 63.82 H: 7.05 N: 4.88 Example 3 3.14 g of trans-4-aminomethylcyclohexanecarboxylic acid and 2.14 g of -isonicotinaldehyde
g and 2.5 g of 10% palladium-carbon were added to 100 ml of ethanol, and catalytic reduction was carried out under heating at 80 to 100° C. for 4 hours. The reaction solution was filtered, the liquid was concentrated under reduced pressure, the precipitated crystals were collected, and recrystallized from methanol to obtain colorless prismatic crystals of trans-4-
2.5 g of (4'-pyridylmethyl)aminomethylcyclohexanecarboxylic acid was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 186-188℃ Infrared absorption spectrum νc=o Mass spectrum M + 248 Elemental analysis value C 14 H 20 N 2 O 2 Theoretical value C: 67.71 H: 8.12 N: 11.28 Actual value C: 67.61 H: 8.04 N: 11.36 Example 4 2.9 g of trans-4-(p-nitrobenzyl)aminomethylcyclohexanecarboxylic acid and 0.3 g of platinum oxide were added to 50 ml of methanol acetic acid (9.5:0.5) and contacted at room temperature at 1 to 2 Kg/ cm2. I made a return. The reaction stops when the theoretical amount of hydrogen has been absorbed,
The reaction solution was filtered, the liquid was concentrated under reduced pressure, the precipitated crystals were collected, and further recrystallized from a mixed solvent of acetone-isopropyl ether to give pale yellow prismatic crystals of trans-4-(p-aminobenzyl)aminomethylcyclohexanecarboxylic acid. 2.4g was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 208-210℃ Infrared absorption spectrum νc=o Mass spectrum M + 262 Elemental analysis value C 15 H 22 N 2 O 2 Theoretical value C: 68.67 H: 8.45 N: 10.68 Actual value C: 68.76 H: 8.31 N: 10.78 Examples 5-12 The compounds of the present invention shown in the following table were synthesized according to the methods of Examples 1-4.

【表】【table】

Claims (1)

【特許請求の範囲】 1 一般式 〔式中、Aは【式】(但し、式中Yは水 素原子、ハロゲン原子、低級アルコキシ基、ニト
ロ基、アミノ基又はトリフルオロメチル基を意味
する)又はピリジル基を意味する〕で表わされる
シクロヘキサンカルボン酸誘導体。
[Claims] 1. General formula [Wherein, A is represented by [Formula] (wherein Y means a hydrogen atom, a halogen atom, a lower alkoxy group, a nitro group, an amino group, or a trifluoromethyl group) or a pyridyl group] Cyclohexanecarboxylic acid derivative.
JP16290980A 1980-11-18 1980-11-18 Cyclohexanecarboxylic acid derivative Granted JPS5785346A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16290980A JPS5785346A (en) 1980-11-18 1980-11-18 Cyclohexanecarboxylic acid derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16290980A JPS5785346A (en) 1980-11-18 1980-11-18 Cyclohexanecarboxylic acid derivative

Publications (2)

Publication Number Publication Date
JPS5785346A JPS5785346A (en) 1982-05-28
JPS6353984B2 true JPS6353984B2 (en) 1988-10-26

Family

ID=15763526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16290980A Granted JPS5785346A (en) 1980-11-18 1980-11-18 Cyclohexanecarboxylic acid derivative

Country Status (1)

Country Link
JP (1) JPS5785346A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0522215U (en) * 1991-09-02 1993-03-23 本田技研工業株式会社 External pipe holding structure
USRE48565E1 (en) 1981-11-03 2021-05-18 Personalized Media Communications LLC Providing a subscriber specific solution in a computer network

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163813A (en) * 1984-02-04 1985-08-26 Morishita Jintan Kk Antiplasmin drug
CA2606804A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
JP2009533315A (en) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド Antibacterial agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48565E1 (en) 1981-11-03 2021-05-18 Personalized Media Communications LLC Providing a subscriber specific solution in a computer network
JPH0522215U (en) * 1991-09-02 1993-03-23 本田技研工業株式会社 External pipe holding structure

Also Published As

Publication number Publication date
JPS5785346A (en) 1982-05-28

Similar Documents

Publication Publication Date Title
US4920131A (en) Quinoline derivatives and use thereof as antagonists of leukotriene D4
KR970005927B1 (en) Pyridine and dyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and process for preparation thereof
DE3834204A1 (en) 4H-1-BENZOPYRAN-4-ON DERIVATIVES OR THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS WITH A CONTENT OF THE SAME AS ACTIVE SUBSTANCE
JP2001505198A (en) Substituted dihydrobenzofurans as PDE inhibitors
CA3053068A1 (en) 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
JPS6033114B2 (en) 1,2-benzisoxazole derivative
JPH01301661A (en) Novel pyridyl derivative
US4977162A (en) Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
JPS6353984B2 (en)
JPH07505394A (en) Bridged bisaryl carbinol derivatives, compositions and uses
CA1208643A (en) 1,5-diphenyl-pyrazolin-3-one compounds, process and intermediates for preparation thereof and pharmaceutical compositions containing them
JPH0673012A (en) 4-iminoquinoline, its preparation and its use
JPS628117B2 (en)
JPS62277392A (en) Sulfenamide derivative and production thereof
JPH0559117B2 (en)
JPS5849369A (en) Novel imidazole compound, manufacture and analgesic antipuretic antiinflammatory drug containing same as major component
CA1078395A (en) Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation
JPS6368568A (en) P-aminophenol derivative
JPH01203351A (en) 1,4-dihydroxynaphthalene derivative and medicine
JPS6127977A (en) 4,5-dihydro-3,3-diphenyl-4-hydrocarbyl aminomethylfuran-2(3h)-one
SARGENT THE SYNTHESIS OF 1-ETHYL-, 2-ETHYL-, 3-ETHYL-AND 4-ETHYL-ACRIDINE1
JPH01121274A (en) 2-substituted cycloheptimidazole derivative, antiulcer agent and production thereof
JPS5993080A (en) 1,5-naphthyridinecarboxylic acid derivative
JPH02270868A (en) Anti-inflammatory 1-heteroaryl-3-acyl-2-oxyindole
JPS6026794B2 (en) 2-Aminochromone-3-carboxaldehyde derivative and method for producing the same